These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 375998)

  • 1. Effects of prostacyclin and albumin on platelet loss during in vitro simulation of extracorporeal circulation.
    Addonizio VP; Macarak J; Nicolaou KC; Edmunds LH; Colman RW
    Blood; 1979 Jun; 53(6):1033-42. PubMed ID: 375998
    [No Abstract]   [Full Text] [Related]  

  • 2. Iloprost (ZK36374), a stable analogue of prostacyclin, preserves platelets during simulated extracorporeal circulation.
    Addonizio VP; Fisher CA; Jenkin BK; Strauss JF; Musial JF; Edmunds LH
    J Thorac Cardiovasc Surg; 1985 Jun; 89(6):926-33. PubMed ID: 2582210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Function of human platelets during extracorporeal circulation.
    Hennessy VL; Hicks RE; Niewiarowski S; Edmunds LH; Colman RW
    Am J Physiol; 1977 Jun; 232(6):H622-8. PubMed ID: 18017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional changes in platelets during extracorporeal circulation.
    Tamari Y; Aledort L; Puszkin E; Degnan TJ; Wagner N; Kaplitt MJ; Peirce EC
    Ann Thorac Surg; 1975 Jun; 19(6):639-47. PubMed ID: 237494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation.
    MacIntyre DE; Handin RI; Rosenberg R; Salzman EW
    Thromb Res; 1981 Apr 1-15; 22(1-2):167-75. PubMed ID: 6270842
    [No Abstract]   [Full Text] [Related]  

  • 6. The generation of TXA2 in human platelet rich plasma and its inhibition by nictindole and prostacyclin.
    Grodzińska L; Marcinkiewicz E
    Pharmacol Res Commun; 1979 Feb; 11(2):133-46. PubMed ID: 375247
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostacyclin: a solution to some problems of extracorporeal circulation. Experiments in greyhounds.
    Longmore DB; Bennett G; Gueirrara D; Smith M; Bunting S; Moncada S; Reed P; Read NG; Vane JR
    Lancet; 1979 May; 1(8124):1002-5. PubMed ID: 86720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of platelet lysis, platelet consumption on oxygenator, and stabilization of platelet membrane with prostacyclin and ibuprofen during cardiopulmonary bypass surgery in dogs.
    Dewanjee MK; Vogel SR; Peterson KA; Lim MF; Kaye MP
    Trans Am Soc Artif Intern Organs; 1981; 27():197-202. PubMed ID: 7036497
    [No Abstract]   [Full Text] [Related]  

  • 9. Is prostacyclin a physiologically important circulating anti-platelet agent?
    Steer ML; MacIntyre DE; Levine L; Salzman EW
    Nature; 1980 Jan; 283(5743):194-5. PubMed ID: 6243178
    [No Abstract]   [Full Text] [Related]  

  • 10. Quantitation of platelet preservation with prostanoids during simulated bypass.
    Kappa JR; Musial J; Fisher CA; Addonizio VP
    J Surg Res; 1987 Jan; 42(1):10-8. PubMed ID: 2433503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptors and receptor mechanisms of endogenous platelet stimulatory and inhibitory mediators.
    MacIntyre DE; Bushfield M; MacMillan LJ; Moffat KJ; Murdoch FA; Thomson A; Rossi AG; McNicol A
    Agents Actions Suppl; 1986; 20():45-62. PubMed ID: 3028106
    [No Abstract]   [Full Text] [Related]  

  • 12. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation.
    Siess W; Roth P; Weber PC
    Thromb Haemost; 1981 Jun; 45(3):204-7. PubMed ID: 7025338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preservation of platelets during extracorporeal circulation with prostaglandin E1.
    Addonizio VP; Macarak EJ; Niewiarowski S; Colman RW; Edmunds LH
    Trans Am Soc Artif Intern Organs; 1977; 23():639-45. PubMed ID: 910394
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
    Eggerman TL; Harker LA; Andersen NH; Wilson CH
    Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
    [No Abstract]   [Full Text] [Related]  

  • 15. Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men.
    Szczeklik A; Gryglewski RJ; Nizankowski R; Musiał J; Pietoń R; Mruk J
    Pharmacol Res Commun; 1978 Jun; 10(6):545-56. PubMed ID: 358212
    [No Abstract]   [Full Text] [Related]  

  • 16. Measurement of circulating prostacyclin.
    Haslam RJ; McClenaghan MD
    Nature; 1981 Jul; 292(5821):364-6. PubMed ID: 7019720
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets.
    Best LC; Martin TJ; Russell RG; Preston FE
    Nature; 1977 Jun; 267(5614):850-2. PubMed ID: 197414
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of blood flow rate and circuit surface area on platelet loss during extracorporeal circulation.
    Addonizio VP; Colman RW; Edmunds LH
    Trans Am Soc Artif Intern Organs; 1978; 24():650-5. PubMed ID: 716073
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of prostacyclin on ultrastructural features of human platelets in vitro.
    Weber G; Bianciardi G; Toti P; Sinzinger H
    Prostaglandins; 1981 Nov; 22(5):789-93. PubMed ID: 7036227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematologic responses to prolonged extracorporeal circulation (ECC) with microporous membrane devices.
    Bartlett RH; Fong SW; Woldanski C; Hung E; Styler D; MacArthur C
    Trans Am Soc Artif Intern Organs; 1975; 21():250-7. PubMed ID: 1145997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.